Literature DB >> 6861700

Testosterone-responsive mouse kidney glycosphingolipids: developmental and inbred strain effects.

R H McCluer, C K Deutsch, S K Gross.   

Abstract

Mouse kidney and urinary glycosphingolipids from developing C57BL/6J and adults of several other inbred strains were analyzed by high performance liquid chromatographic techniques. Glycosphingolipids from male and female C57BL/6J kidneys were similar until the fifth week of age. Galactosylceramide containing nonhydroxy fatty acids and galabiglycosylceramide containing nonhydroxy fatty acids first appeared in male kidneys, followed by an increase in galabiglycosylceramide containing hydroxy fatty acids. Galabiglycosylceramide was observed in male urine from the earliest collection period (26 days of age). At 5 weeks, globotriglycosylceramides were present in male urine, and by 6 weeks, they became the major glycolipid species. Analysis of the glycosphingolipids from adult male and female DBA/2J, CBA/J, C3H/HeJ, and AKR/J kidneys revealed that galactosylceramides and galabiglycosylceramides which contain nonhydroxy fatty acids were absent in all females and present in all males. The globotriglycosylceramides were elevated in male kidneys of all strains. Galabiglycosylceramides and globotriglycosylceramides were present in male urine of all strains. Each strain exhibited a characteristic pattern of urinary glycosphingolipids which varied not only in the different levels of di- and triglycosylceramides but also in the ratio of components that are distinguished by their fatty acid and long chain base composition. These data provide evidence that in several inbred strains of mice, testosterone induces the production of specific di- and triglycosylceramides, which are components of lysosomal organelles that are normally excreted in the urine.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6861700     DOI: 10.1210/endo-113-1-251

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

1.  Sex differences of urinary and kidney globotriaosylceramide and lyso-globotriaosylceramide in Fabry mice.

Authors:  Brandon Durant; Sabrina Forni; Lawrence Sweetman; Nastry Brignol; Xing-Li Meng; Elfrida R Benjamin; Raphael Schiffmann; Jin-Song Shen
Journal:  J Lipid Res       Date:  2011-07-11       Impact factor: 5.922

2.  Sex- and age-related differences in ceramide dihexosides of primary human brain tumors.

Authors:  A J Yates; T K Franklin; B W Scheithauer; P C Burger; D K Pearl
Journal:  Lipids       Date:  1999-01       Impact factor: 1.880

3.  Effect of globotriaosyl ceramide fatty acid alpha-hydroxylation on the binding by verotoxin 1 and verotoxin 2.

Authors:  Beth Binnington; Daniel Lingwood; Anita Nutikka; Clifford A Lingwood
Journal:  Neurochem Res       Date:  2002-08       Impact factor: 3.996

4.  Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice.

Authors:  Y A Ioannou; K M Zeidner; R E Gordon; R J Desnick
Journal:  Am J Hum Genet       Date:  2000-12-13       Impact factor: 11.025

5.  Expression of glycosphingolipids in serum-free primary cultures of mouse kidney cells: male-female differences and androgen sensitivity.

Authors:  S K Gross; T A Lyerla; J E Evans; R H McCluer
Journal:  Mol Cell Biochem       Date:  1994-08-17       Impact factor: 3.396

6.  Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease.

Authors:  Karen M Ashe; Eva Budman; Dinesh S Bangari; Craig S Siegel; Jennifer B Nietupski; Bing Wang; Robert J Desnick; Ronald K Scheule; John P Leonard; Seng H Cheng; John Marshall
Journal:  Mol Med       Date:  2015-04-30       Impact factor: 6.354

7.  Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients.

Authors:  Brandy Young-Gqamana; Nastry Brignol; Hui-Hwa Chang; Richie Khanna; Rebecca Soska; Maria Fuller; Sheela A Sitaraman; Dominique P Germain; Roberto Giugliani; Derralynn A Hughes; Atul Mehta; Kathy Nicholls; Pol Boudes; David J Lockhart; Kenneth J Valenzano; Elfrida R Benjamin
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.